SULTEN-10 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulten-10, and when can generic versions of Sulten-10 launch?
Sulten-10 is a drug marketed by Bausch And Lomb and is included in one NDA.
The generic ingredient in SULTEN-10 is sulfacetamide sodium. There are three drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sulten-10
A generic version of SULTEN-10 was approved as sulfacetamide sodium by SANDOZ on October 18th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SULTEN-10?
- What are the global sales for SULTEN-10?
- What is Average Wholesale Price for SULTEN-10?
Summary for SULTEN-10
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Patent Applications: | 819 |
| DailyMed Link: | SULTEN-10 at DailyMed |
US Patents and Regulatory Information for SULTEN-10
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | SULTEN-10 | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 087818-001 | Feb 3, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
